Meridian Bioscience Inc
NASDAQ:VIVO
Meridian Bioscience Inc
NASDAQ:VIVO
Price:
33.97 USD
Market Closed
Updated:
May 11, 2024
P/E
Price to Earnings
Price to Earnings
35
Current
18.6
Median
23.9
Industry
Higher
than median
Higher
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=35
Market Cap
/
1.5B
Net Income
42.5m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Meridian Bioscience Inc
NASDAQ:VIVO
|
1.5B USD | 35 | |
| JP |
|
Hoya Corp
TSE:7741
|
6.3T JPY | 38 | |
| CH |
|
Alcon AG
SIX:ALC
|
36.3B CHF | 41.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
190B DKK | 39 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
20.4B USD | 44.2 | |
| US |
|
Cooper Companies Inc
NYSE:COO
|
18.8B USD | 64.7 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
13.1T KRW | -69.4 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
61.2B CNY | 35.5 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5.4B GBP | 51.6 | |
| US |
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | -60.9 | |
| CA |
B
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.4B USD | -16.1 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
40.3
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A
You don't have any saved screeners yet
